Exhibit 99.1 Teladoc Health Reports Full Year and Fourth Quarter 2024 Results PURCHASE, NY, February 26, 2025—Teladoc Health, Inc. (NYSE: TDOC), the global leader in whole-person virtual care, today reported financial results for the full year ended December 31, 2024 ("Full Year 2024") and three months ended December 31, 2024 ("Fourth Quarter 2024"). Unless otherwise noted, percentage and other changes are relative to the full year ended December 31, 2023 ("Full Year 2023") and three months ended December 3 ...

Core Insights - Teladoc Health reported a net loss of $1,001.2 million for the full year 2024, significantly higher than the $220.4 million loss in 2023, primarily due to a non-cash goodwill impairment charge of $790 million related to the BetterHelp segment [7][13][12] - The company experienced a 1% decline in total revenue for the full year 2024, totaling $2,569.6 million compared to $2,602.4 million in 2023 [7][11] - Integrated Care segment revenue increased by 4% year-over-year, while BetterHelp segment revenue decreased by 8% for the full year 2024 [12][15] Financial Performance - Fourth Quarter 2024 revenue decreased by 3% to $640.5 million from $660.5 million in the same quarter of 2023 [6][7] - The net loss for Fourth Quarter 2024 was $48.4 million, compared to a loss of $28.9 million in Fourth Quarter 2023 [8][7] - Adjusted EBITDA for Fourth Quarter 2024 was $74.8 million, down 35% from $114.4 million in Fourth Quarter 2023 [9][15] Revenue Breakdown - Access fees revenue for Fourth Quarter 2024 decreased by 5% to $543.1 million, while other revenue grew by 12% to $97.4 million [6][11] - U.S. revenue decreased by 5% to $535.4 million, while international revenue grew by 10% to $105.1 million in Fourth Quarter 2024 [6][11] - For the full year 2024, U.S. revenue decreased by 3% to $2,160.0 million, while international revenue increased by 12% to $409.6 million [11][12] Cost and Cash Flow - Operating cash flow for the full year 2024 was $293.7 million, down from $350.0 million in 2023 [7][17] - Free cash flow for the full year 2024 was $169.6 million, compared to $193.7 million in 2023 [7][18] - Capital expenditures for the full year 2024 were $124.1 million, down from $156.3 million in 2023 [18] Future Outlook - For the full year 2025, Teladoc expects revenue in the range of $2,468 million to $2,576 million and adjusted EBITDA between $278 million and $319 million [19][20] - The company anticipates a net loss per share for 2025 in the range of ($1.10) to ($0.50) [20][21] - The guidance includes contributions from the acquisition of Catapult Health, expected to close at the end of February 2025 [19][20]

Core Viewpoint - Edelson Lechtzin LLP is investigating potential violations of federal securities laws involving Teladoc Health Inc. due to allegations of misleading business information provided to investors [1] Company Overview - Teladoc Health is a telemedicine and virtual healthcare provider [2] Allegations of Wrongdoing - Blue Orca Capital has issued a report claiming a short position in Teladoc, alleging that the company provides mental health therapy through an AI platform rather than licensed therapists. This practice incentivizes therapists to generate longer, generic messages, which can be easily produced by AI [3] - Therapists are reportedly compensated based on the quantity of words in their responses, leading to potential quality issues in patient communication [3] - Blue Orca's claims are supported by field research, including patient interviews where therapists admitted to using AI in communications [3] Accounting Practices - Blue Orca alleges that Teladoc is using questionable accounting techniques to inflate profitability and cash flows by shifting R&D expenses from the income statement to investing cash flows. This manipulation reportedly inflated EBITDA by up to 32% and operating cash flows by 127% for FY 2023 [4] Profitability Concerns - Blue Orca believes that Teladoc is less profitable and generates significantly less cash than investors are led to believe. The use of AI in mental health treatment is expected to lead to a deterioration of that business and a decline in stock price [5]

Core Insights - Analysts project that Teladoc (TDOC) will report a quarterly loss of $0.21 per share, reflecting a year-over-year decline of 23.5% [1] - Revenue is expected to reach $639.5 million, down 3.2% from the same quarter last year [1] - There have been no revisions in the consensus EPS estimate over the last 30 days, indicating analysts' stable outlook [1] Revenue Projections - The consensus estimate for 'Revenues by Segment- BetterHelp' is $246.59 million, indicating a decline of 10.7% year-over-year [4] - 'Revenues by Segment- Teladoc Health Integrated Care' is projected at $389.73 million, suggesting a slight increase of 1.4% year-over-year [4] - 'Revenues by Segment- BetterHelp- Therapy Services' is expected to be $240.36 million, down 11.4% from the prior year [5] - 'Revenues by Segment- BetterHelp- Other Wellness Services' is anticipated to reach $6.36 million, reflecting a significant increase of 29.9% year-over-year [5] Revenue by Type - Analysts expect 'Revenue by Type- Access fees' to be $543.58 million, indicating a decrease of 5.3% from the previous year [6] - The consensus for 'Revenue by Type- Other' stands at $83.99 million, showing a year-over-year decline of 3% [6] Membership and EBITDA Estimates - The projected number of 'U.S. Integrated Care Members' is 94.17 million, an increase from 89.6 million reported in the same quarter last year [6] - 'Adjusted EBITDA- BetterHelp' is expected to be $29.00 million, down from $58.47 million a year ago [7] - 'Adjusted EBITDA- Teladoc Health Integrated Care' is projected at $51.62 million, compared to $55.97 million in the prior year [7] Stock Performance - Teladoc shares have increased by 25.2% over the past month, outperforming the Zacks S&P 500 composite, which rose by 2.2% [7] - The company holds a Zacks Rank 3 (Hold), indicating it is expected to closely follow overall market performance in the near term [7]

Group 1 - Block & Leviton is investigating Teladoc Health, Inc. for potential securities law violations following a report by Blue Orca Capital [1][2] - Teladoc Health's shares fell over 12% on February 20 due to allegations of misleading investors regarding its BetterHelp platform and financial reporting [2] - The allegations include the use of AI-generated responses instead of licensed therapists and accusations of inflating profitability by shifting R&D expenses [2] Group 2 - Investors who have lost money in Teladoc Health, Inc. may be eligible to recover losses and are encouraged to contact Block & Leviton [3][4] - Block & Leviton is recognized as a leading securities class action firm, having recovered billions for defrauded investors [7] - Whistleblowers with non-public information about Teladoc Health, Inc. may assist in the investigation and could receive rewards from the SEC [6]

Core Viewpoint - Teladoc Health, Inc. is under investigation for potential securities law violations following a report from Blue Orca Capital, which alleges misleading practices regarding its BetterHelp platform and financial reporting [2][4]. Group 1: Investigation Details - Block & Leviton is investigating Teladoc Health for possible securities law violations and may file an action to recover losses for affected investors [4]. - The investigation was prompted by a report claiming that BetterHelp utilized AI-generated responses instead of licensed therapists without proper disclosures [2]. - The report also accuses Teladoc of inflating profitability by shifting research and development expenses [2]. Group 2: Investor Eligibility - Any investor who purchased Teladoc Health common stock and experienced a decline in share value may be eligible to participate in the investigation, regardless of whether they sold their investment [3]. Group 3: Whistleblower Information - Individuals with non-public information about Teladoc Health are encouraged to assist in the investigation or report to the SEC under the whistleblower program, potentially receiving rewards of up to 30% of any successful recovery [6]. Group 4: Firm Background - Block & Leviton is recognized as a leading securities class action firm, having recovered billions for defrauded investors and representing many top institutional investors [7].

Group 1 - Teladoc (NYSE: TDOC) experienced significant positive momentum over the past three months, largely driven by investor optimism and speculation regarding its potential in the AI sector [1] - The narrative surrounding Teladoc's overlooked AI capabilities gained traction following the company's recent announcements [1] Group 2 - The article emphasizes the importance of data analytics in identifying investment opportunities within the equity markets, highlighting the vast amount of data available from SEC filings and other sources [1]

Core Viewpoint - Citron Research identifies Teladoc Health as a hidden opportunity in the AI sector within telemedicine, despite its current perception as a "pandemic relic" [2][5]. Company Performance - Teladoc's stock peaked at nearly $300 during the COVID-19 pandemic but has since dropped significantly, trading at 95% below its all-time highs as of February 10 [3][9]. - The company experienced a surge in demand for telemedicine services during the pandemic, which has since slowed down post-economic reopening [4][5]. Financial Metrics - While revenue growth has plateaued, Teladoc's free cash flow has been increasing, indicating improved operational efficiencies and higher profit margins [6][5]. - Citron suggests that Teladoc's current valuation appears attractive on a price-to-free-cash-flow basis, despite the stock being perceived as oversold [9]. Technology and AI Integration - Citron claims that Teladoc is effectively utilizing technology, although the company did not mention "artificial intelligence" during its recent earnings call, indicating that AI may not be a priority [8][10]. - The potential for Teladoc to be an acquisition target for larger companies like Amazon or CVS Health is highlighted, although this remains speculative [8][10]. Investment Outlook - Despite the positive aspects noted by Citron, there is skepticism regarding the narratives of Teladoc being a hidden AI gem or a likely acquisition candidate, suggesting that the stock may not be a solid buy at this time [11].

Company Overview - Teladoc Health shares increased by 8.8% in the last trading session, closing at $11.97, with notable trading volume compared to typical sessions [1] - The stock has gained 12.5% over the past four weeks, indicating positive momentum [1] Recent Developments - The recent rally in Teladoc's stock is attributed to optimism surrounding its acquisition of Catapult Health and endorsement from Citron Research, which labeled it an "Under-the-Radar AI Play" [2] - The company is focusing on strategic technology investments, particularly in AI, to enhance profitability [2] Financial Expectations - Teladoc is expected to report a quarterly loss of $0.21 per share, reflecting a year-over-year decline of 23.5% [3] - Revenue projections stand at $639.5 million, which is a decrease of 3.2% compared to the same quarter last year [3] Earnings Estimates and Stock Performance - The consensus EPS estimate for Teladoc has remained unchanged over the last 30 days, suggesting stability in earnings expectations [4] - Historical trends indicate that stock prices typically do not continue to rise without changes in earnings estimate revisions, highlighting the importance of monitoring Teladoc's performance moving forward [4] Industry Context - Teladoc is part of the Zacks Medical Services industry, which includes other companies like Sonida Senior Living [4] - Sonida Senior Living has a consensus EPS estimate of -$0.71 for its upcoming report, representing a 67.3% improvement from the previous year [5]

Shares of telemedicine company Teladoc Health (TDOC 8.82%) surprisingly popped on Thursday after Citron Research gave it a glowing recommendation. As of 3:30 p.m. ET, Teladoc stock was up 7%, but it had been up as much as 15% earlier in the day.Is this a sudden cash-flow opportunity?Teladoc stock has been completely discarded by investors. A stock market darling in 2020, it's dropped 96% from its all-time high in early 2021. This is why the shoutout from Citron Research was so surprising. The research firm ...